Treatment for Myelofibrosis

     A sign of myelofibrosis is the disruption of the normal production of blood cells by the bone marrow. This disruption leads to scarring of the bone marrow, which impairs its ability to produce different types of cells. Normally, stem cells in the bone marrow lead to the development of red blood cells, white blood cells, and platelets.  Anemia, increased risk of infections, and bleeding conditions can develop as a result of myelofibrosis. Bone pain can also result.  In response to the deficiency, the liver and spleen attempt to produce the cells that are lacking, and these organs can become enlarged. A genetic mutation leads to myelofibrosis, although the exact cause of the mutation is unknown.Persons over age 50 are more likely than others to develop the condition.

     A stem cell transplant is the only treatment currently available for a cure of myelofibrosis. Medications are available to treat conditions that may develop as a result of myelofibrosis for persons who are not able to receive a transplant. Hydroxyurea (Hydrea) works to decrease the size of an enlarged spleen, normalize cell production, and improve bone pain and other symptoms. Fluoxymesterone (Androxy) may be prescribed along with prednisone, to improve production of red blood cells for persons with anemia.